Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Arthritis, Psoriatic,Colitis, Ulcerative,Arthritis, Juvenile Rheumatoid,Spondylitis, Ankylosing,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 21/03/2017, Revision: 6, Status: Authorised